By Dr Louise Emmett

Journal articles

Russell M; Emmett L; Peric B; Saw R; Spillane J; Vazquez V; Duprat J; Moncreiff M; Allan C; Leeuwen BV; Pritchard-Jones R; Rastrelli M; de Wilt H; Geh J; Howle J; Spillane A, 2024, 'Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial', European Journal of Surgical Oncology, 50, pp. 107397 - 107397, http://dx.doi.org/10.1016/j.ejso.2023.107397

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua A; Emmett L; Murphy D; Hsiao E; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS, 2024, 'LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)', Annals of Oncology, 35, pp. S1255 - S1256, http://dx.doi.org/10.1016/j.annonc.2024.08.2309

Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes AM; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ, 2023, 'Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography', European Urology Oncology, 6, pp. 553 - 563, http://dx.doi.org/10.1016/j.euo.2023.03.010

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne H; Tunariu N; Ho B; Young S; Singbo MNU; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial', Cancer Imaging, 23, http://dx.doi.org/10.1186/s40644-023-00570-x

Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G, 2023, 'Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer', Radiation Oncology, 18, http://dx.doi.org/10.1186/s13014-023-02302-8

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J, 2023, '68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study', Translational Andrology and Urology, 12, pp. 1598 - 1606, http://dx.doi.org/10.21037/tau-22-708

Pouliot F; Emmett L, 2023, 'Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now', European Urology, 84, pp. 371 - 372, http://dx.doi.org/10.1016/j.eururo.2023.07.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Roberts MJ; Hruby G; Kneebone A; Martin JM; Williams SG; Frydenberg M; Murphy DG; Namdarian B; Yaxley JW; Hofman MS; Davis ID; Emmett L, 2023, 'Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?', BJU International, 132, pp. 146 - 148, http://dx.doi.org/10.1111/bju.16086

Mei R; Kessler L; Pabst KM; Weber M; Schmidkonz C; Rischpler C; Zacho HD; Hope T; Schwarzenbock SM; Allen-Auerbach M; Emmett L; Ferdinandus J; Unterrainer M; Schaarschmidt BM; Umutlu L; Farolfi A; Castellucci P; Nanni C; Telo S; Fanti S; Herrmann K; Fendler WP, 2023, '68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study', Journal of Nuclear Medicine, 64, pp. 1043 - 1048, http://dx.doi.org/10.2967/jnumed.122.265245

Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D, 2023, 'A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy', European Urology Open Science, 53, pp. 90 - 97, http://dx.doi.org/10.1016/j.euros.2023.05.002

Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K, 2023, 'Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2830 - 2845, http://dx.doi.org/10.1007/s00259-023-06255-8

Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C, 2023, 'PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2529 - 2536, http://dx.doi.org/10.1007/s00259-023-06185-5

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2023, 'Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study', Radiotherapy and Oncology, 184, http://dx.doi.org/10.1016/j.radonc.2023.109678

Lengyelova E; Wong V; Lenzo N; Parker M; Emmett L, 2023, '⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.', Journal of Clinical Oncology, 41, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5039

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Unterrainer L; Farolfi A; Rosar F; Emmett L; Denis C; Hope T; Hotta M; de Kouchkovsky I; Djaileb L; Gafita A; Czernin J; Calais J, 2023, 'Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: an international multicenter, retrospective analysis', JOURNAL OF NUCLEAR MEDICINE, 64

Soon YY; Marschner I; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2023, 'Effects of [¹⁷⁷Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.', Journal of Clinical Oncology, 41, pp. 5045 - 5045, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5045

Feldman DR; Tran B; Emmett L; Hofman MS; Olivier P; Mahammedi H; Galetic I; Pokorska-Bocci A; Bouisset F; Gollmer K; Pavlyuk M; Tauchmanova L; Herrmann K, 2023, 'First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.', Journal of Clinical Oncology, 41, pp. TPS3160 - TPS3160, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3160

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS, 2023, 'Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer', JAMA Network Open, 6, http://dx.doi.org/10.1001/jamanetworkopen.2023.14748

Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M, 2023, 'Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)', European Urology, 83, pp. 405 - 412, http://dx.doi.org/10.1016/j.eururo.2023.02.002

Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L, 2023, 'Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer', BJU International, 131, pp. 588 - 595, http://dx.doi.org/10.1111/bju.15929

Zamboglou C; Arnoux A; Janbain A; Strouthos I; Farolfi A; Koerber S; Peeken J; Vogel M; Ferentinos K; Shelan M; Grosu AL; Kroeze S; Guckenberger M; Fanti S; Hruby G; Scharl S; Wiegel T; Henkeberens C; Emmett L; Hegemann N-S, 2023, 'Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy in recurrent prostate cancer.', JOURNAL OF CLINICAL ONCOLOGY, 41

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Weickhardt AJ; Lee ST; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001).', JOURNAL OF CLINICAL ONCOLOGY, 41

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne HA; Tunariu N; Ho B; Young S; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.', JOURNAL OF CLINICAL ONCOLOGY, 41

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', JOURNAL OF CLINICAL ONCOLOGY, 41

Emmett L; Wong V; Lenzo N; Lengyelova E; Biggin C, 2023, 'Positron emission tomography of patients with confirmed prostate cancer using ⁶⁴Cu-SARbisPSMA.', JOURNAL OF CLINICAL ONCOLOGY, 41

Buteau JP; Moon D; Fahey MT; Roberts M; Thompson J; Murphy DG; Papa N; Mitchell C; Kasivisvanathan V; Stricker P; O'Brien J; Counter W; Sharma G; Agrawal S; Ho B; Yeung T; Lourenco RDA; Dhillon HM; Hofman MS; Emmett L, 2023, 'PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [⁶⁸Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.', JOURNAL OF CLINICAL ONCOLOGY, 41

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G, 2023, 'Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium–Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes', International Journal of Radiation Oncology Biology Physics, 115, pp. 106 - 117, http://dx.doi.org/10.1016/j.ijrobp.2022.05.044

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Roberts MJ; Maurer T; Perera M; Eiber M; Hope TA; Ost P; Siva S; Hofman MS; Murphy DG; Emmett L; Fendler WP, 2023, 'Using PSMA imaging for prognostication in localized and advanced prostate cancer', Nature Reviews Urology, 20, pp. 23 - 47, http://dx.doi.org/10.1038/s41585-022-00670-6

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', ANNALS OF ONCOLOGY, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; Pasam A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, 'Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', ANNALS OF ONCOLOGY, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Zamboglou C; Ferentinos K; Arnoux A; Janbain A; Strouthose I; Farolfi A; Koerber S; Peeken J; Vogel M; Vrachimis A; Spohn SKB; Shelan M; Grosu A; Kroeze S; Guckenberger M; Fanti SF; Belka C; Hruby G; Scharl S; Wiegel T; Henkenberens C; Emmett L; Schmidt-Hegemann NS, 2023, 'OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer', Radiotherapy and Oncology, 182, pp. S335 - S336, http://dx.doi.org/10.1016/s0167-8140(23)08607-3

Scheltema MJV; Geboers B; Meijer D; Counter W; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; Vis A; van Leeuwen P; Ho B; Liu V; Lee J; Donswijk M; Oprea-Lager D; Emmett L; Stricker P, 2023, 'The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer', European Urology Open Science, 57, pp. S45 - S45, http://dx.doi.org/10.1016/s2666-1683(23)01325-3

van Leeuwen PJ; Emmett L, 2022, '¹⁸F-PSMA-11 as an Attractive ⁶⁸Ga-PSMA-11 Alternative for Prostate Cancer Imaging', European Urology, 82, pp. 510 - 511, http://dx.doi.org/10.1016/j.eururo.2022.06.001

Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L, 2022, 'Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups', BJU International, 130, pp. 32 - 39, http://dx.doi.org/10.1111/bju.15762

Ptasznik G; Papa N; Kelly BD; Thompson J; Stricker P; Roberts MJ; Hofman MS; Buteau J; Murphy DG; Emmett L; Moon D, 2022, 'High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer', BJU International, 130, pp. 5 - 7, http://dx.doi.org/10.1111/bju.15736

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS; Akhurst T; Alipour R; Banks P; Beaulieu A; Chua W; Dhiantravan N; Ford K; Gedye C; Goh JC; Guminski A; Hamid A; Haskali MB; Hicks RJ; Hsiao E; Kirkwood ID; Kong G; Kwan EM; Langford A; Lawrence N; Lewin J; Lin P; McDonald W; Moodie K; Murphy DG; Ng S; Pattison DA; Pokorski I; Ramdave S; Ravi Kumar AS; Redfern AD; Rutherford NK; Saghebi J; Spain L; Subramaniam S; Tan TH; Thang SP; Tran B; Wallace R; Weickhardt A; Yip S, 2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2

Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS, 2022, 'The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis', Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 63, pp. 1644 - 1650, http://dx.doi.org/10.2967/jnumed.121.263448

Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A, 2022, 'EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy', European Urology Oncology, 5, pp. 530 - 536, http://dx.doi.org/10.1016/j.euo.2022.05.003

Pomykala KL; Herrmann K; Emmett L; Lalumera E; Fanti S, 2022, 'Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?', European Urology Open Science, 44, pp. 11 - 12, http://dx.doi.org/10.1016/j.euros.2022.07.015

Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L, 2022, 'Diagnostic value of ⁶⁸Ga-DOTATATE PET-CT imaging for staging of ER⁺/PR⁺ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and ¹⁸F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772

Roberts MJ; Morton A; Papa N; Franklin A; Raveenthiran S; Yaxley WJ; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Emmett L; Yaxley JW, 2022, 'Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 49, pp. 3289 - 3294, http://dx.doi.org/10.1007/s00259-022-05756-2

Back to profile page